TY  - JOUR
T1  - ANtiplatelet therapy following myocardial infarction in patients with diabetes
AU  - Bhatt DL
Y1  - 2012/09/05
N1  - 10.1001/2012.jama.11467
JO  - JAMA
SP  - 921
EP  - 922
VL  - 308
IS  - 9
N2  - 
In this issue of JAMA, Andersson et al3 present a careful analysis of patients who have survived 30 days after discharge for a first-time MI in the Danish nationwide registry. The authors examine the benefit of the oral antiplatelet agent clopidogrel in 7247 patients with vs 51 604 without medication-treated diabetes. Consistent with other data, patients with diabetes had a significantly higher rate of mortality and reinfarction (25% vs 15%) over the follow-up period of up to 1 year. Notably, the apparent beneficial effect of clopidogrel vs no clopidogrel was lower in patients with than in those without diabetes: adjusted hazard ratios of 0.89 vs 0.75 for all-cause mortality, 0.93 vs 0.77 for cardiovascular mortality, and 1.00 vs 0.91 for the composite of death or reinfarction.

SN  - 0098-7484
M3  - doi: 10.1001/2012.jama.11467
UR  - http://dx.doi.org/10.1001/2012.jama.11467
ER  -